ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CUE vs MGNX // EV/EBITDA & P/E VALUATION

Cue Biopharma Inc. (NASDAQ) VS. MacroGenics Inc. (NASDAQ) • 15-METRIC TALLY: CUE 4 — MGNX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUE VS. MGNX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CUE MGNX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -14.03% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -48.70% -11.30 MGNX /operating-margins <GO>
Net Profit Margin -60.00% 0.00% -60.00 MGNX /net-margins <GO>
Revenue Growth (YoY) 180.00% -0.30% +180.30 CUE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 CUE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.7 33.0 +13.71 CUE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $155.8M $151.6M $4.2M CUE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CUE REV MGNX REV CUE GROSS % MGNX GROSS % CUE FCF MGNX FCF
FY 2025 $27.5M $149.5M — 98.0% -$21.9M -$83.0M
FY 2024 $9.3M $150.0M — 98.0% -$36.4M -$72.1M
FY 2023 $5.5M $58.7M — — -$40.0M -$78.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUE // BETA —
MGNX // BETA —